Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue

PLoS One. 2016 Feb 3;11(2):e0145937. doi: 10.1371/journal.pone.0145937. eCollection 2016.

Abstract

Introduction: Left ventricular dysfunction is a frequent and potentially severe side effect of many tyrosine kinase inhibitors (TKI). The mode of toxicity is not identified, but may include impairment of mitochondrial or sarcomeric function, autophagy or angiogenesis, either as an on-target or off-target mechanism.

Methods and results: We studied concentration-response curves and time courses for nine TKIs in three-dimensional, force generating engineered heart tissue (EHT) from neonatal rat heart cells. We detected a concentration- and time-dependent decline in contractile force for gefitinib, lapatinib, sunitinib, imatinib, sorafenib, vandetanib and lestaurtinib and no decline in contractile force for erlotinib and dasatinib after 96 hours of incubation. The decline in contractile force was associated with an impairment of autophagy (LC3 Western blot) and appearance of autophagolysosomes (transmission electron microscopy).

Conclusion: This study demonstrates the feasibility to study TKI-mediated force effects in EHTs and identifies an association between a decline in contractility and inhibition of autophagic flux.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autophagy / drug effects
  • Cardiotoxins / pharmacology*
  • Feasibility Studies
  • Myocardial Contraction / drug effects*
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / diagnostic imaging
  • Myocytes, Cardiac / drug effects
  • Protein Kinase Inhibitors / toxicity*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Rats
  • Rats, Inbred Lew
  • Rats, Wistar
  • Tissue Engineering* / methods
  • Ultrasonography

Substances

  • Cardiotoxins
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases